ATN 021B: PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN HIV-INFEC

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 本研究是一项横断面调查，旨在评估HIV感染和未感染男性青年的脂肪分布、葡萄糖、脂质代谢和BMD改变的患病率和严重程度，以及与其存在相关的药物和非药物因素。尽管在艾滋病毒治疗方面取得了不可否认的进展，但现在很明显，许多接受这些治疗方案的患者正在发生潜在的有害代谢并发症，包括胰岛素抵抗、血脂异常、脂肪分布改变、骨质减少、骨质疏松症以及不太常见的高乳酸血症。尽管HIV感染患者中与这些并发症相关的长期风险尚不清楚，但越来越多的人担心，这些并发症可能会影响由于HAART有效抑制病毒而显著延长预期寿命的患者的长期预后。在这项研究中，形态和代谢异常的艾滋病毒感染的高风险的未感染艾滋病毒的青年和艾滋病毒感染的青年对不同类型的抗逆转录病毒药物的患病率将被确定。约250名年龄在12岁0天和24岁364天之间的男性青年将入组4个研究组：一组50名HIV阴性受试者;一组100名HIV阳性受试者，他们正在接受抗逆转录病毒治疗;两组各50名HIV阳性受试者，一组接受基于NNRTI的方案，另一组接受基于PI的方案。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is a cross-sectional survey designed to evaluate the prevalence and severity of alterations in fat distribution, glucose, lipid metabolism, and BMD in HIV-infected and -uninfected male youth as well as drug and non-drug factors related to their presence. Despite unarguable advances in HIV care associated with highly active antiretroviral therapy, it is now apparent that many patients on these regimens are developing potentially deleterious metabolic complications, which include insulin resistance, dyslipidemia, alterations in fat distribution, osteopenia, osteoporosis, and, less commonly, hyperlactatemia. Although the long-term risks associated with these complications in patients with HIV infection are unknown, there is mounting concern that they may impact the long-term prognosis in patients whose life expectancies are significantly extended due to effective viral suppression by HAART. In this study, the prevalence of morphological and metabolic abnormalities in HIV-uninfected youth at high risk for HIV infection and HIV-infected youth on different types of antiretroviral medications will be determined. Approximately 250 male youth between the ages of 12 years, 0 days and 24 years, 364 days will be enrolled in four study groups: a group of 50 HIV-negative subjects; a group of 100 HIV-positive subjects who are antiretroviral therapy nanve; and two groups of up to 50 HIV-positive subjects each, one on an NNRTI-based regimen and the other on a PI-based regimen.